陇神戎发(300534) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥73,114,084.33, an increase of 23.91% year-over-year, and cumulative revenue for the year-to-date was ¥223,495,536.74, up 34.08% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥3,487,713.26, a significant increase of 141.13% year-over-year, with year-to-date net profit reaching ¥5,448,737.60, up 166.56%[4] - Basic earnings per share for Q3 2022 was ¥0.0115, reflecting a 141.07% increase year-over-year, while diluted earnings per share also stood at ¥0.0115[4] - The net profit for the third quarter of 2022 was CNY 10,941,459.65, a recovery from a loss of CNY 11,301,095.59 in the same quarter of the previous year[38] - The net profit for the third quarter of 2022 was CNY 8,612,144.62, a significant recovery from a net loss of CNY 7,123,107.42 in the same period last year[39] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥847,840,389.23, representing a 2.88% increase from the end of the previous year[4] - As of September 30, 2022, the total assets of Gansu Longshen Rongfa Pharmaceutical Co., Ltd. amounted to CNY 847,840,389.23, an increase from CNY 824,072,928.05 at the beginning of the year, reflecting a growth of approximately 2.3%[35] - The total liabilities of the company as of September 30, 2022, were CNY 106,392,745.98, compared to CNY 91,237,429.42 at the beginning of the year, reflecting an increase of about 16.6%[36] - The company’s equity attributable to shareholders increased to CNY 725,698,825.18 from CNY 720,250,087.58, a growth of approximately 0.6%[36] Cash Flow and Operating Activities - Cash flow from operating activities decreased by 66.72% year-over-year, primarily due to increased cash payments for goods and services[20] - The cash flow from operating activities showed a net inflow of CNY 9,896,329.96, down from CNY 29,739,129.06 in the previous year, reflecting a decrease of about 66.7%[40] - The company reported cash and cash equivalents at the end of the period amounting to CNY 98,490,059.04, compared to CNY 61,708,197.65 at the same time last year, representing an increase of approximately 59.7%[41] Inventory and Expenses - Inventory increased by 50.47% compared to the beginning of the period, as the company ramped up production to ensure sufficient supply for the sales peak[9] - Operating costs for the third quarter of 2022 were CNY 215,200,994.16, up from CNY 181,784,660.37 in the previous year, indicating an increase of approximately 18.3%[38] - The company incurred a total operating expense of CNY 245,086,729.72, which is an increase from CNY 202,671,500.97 in the previous year, reflecting a rise of about 20.9%[40] - The company reported a 37.3% increase in selling expenses, attributed to ongoing investments in market development and brand promotion[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,937, with the largest shareholder holding 29.93% of the shares[22] - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. reported a total of 1,351,000 shares held by Gansu Provincial State-owned Assets Investment Group Co., Ltd. as a major shareholder[23] - The company has a total of 1,538,322 restricted shares at the end of the reporting period, with 384,580 shares added during the period[25] Management and Corporate Changes - The company appointed Song Minping as the new chairman of the board on May 26, 2022, following the resignation of the previous chairman[29] - The company’s management team underwent significant changes, including the resignation of the CFO and other key personnel in April 2022[26] - The company signed a management entrustment agreement with Gansu Agricultural Reclamation Group, with a management fee of RMB 600,000, effective for 12 months[27] - The company has not reported any significant decline in operating performance exceeding 20% during the management entrustment period[27] Regulatory Compliance and Licenses - The company received a renewed Drug Production License from the Gansu Provincial Drug Administration on January 18, 2022[26] - The company is focused on maintaining compliance with regulatory requirements, as evidenced by the renewal of its Food Production License[26] - The company obtained a new business license from the Gansu Provincial Market Supervision Administration on May 30, 2022, due to a change in the legal representative[30] Investments and Acquisitions - The company has completed the acquisition of a 70% stake in Puan Pharmaceutical through cash transactions, enhancing its market position[31] - Gansu Longshen Rongfa Pharmaceutical has obtained a new food production license for health food products, indicating ongoing expansion in product offerings[33] Product Development and Market Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[25] - The company did not report any new product launches or technological advancements during this quarter[39] - There were no significant mergers or acquisitions reported in this quarter[39] Audit and Reporting - The report was not audited, indicating that the figures presented are subject to further verification[42]